Deutsche Bank AG Sells 256,311 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Deutsche Bank AG lessened its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 6.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,875,708 shares of the biotechnology company's stock after selling 256,311 shares during the quarter. Deutsche Bank AG owned approximately 1.64% of ADMA Biologics worth $66,468,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. GAMMA Investing LLC increased its position in ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock valued at $32,000 after acquiring an additional 967 shares during the period. Mark Sheptoff Financial Planning LLC bought a new stake in shares of ADMA Biologics in the fourth quarter worth $35,000. Vision Financial Markets LLC acquired a new stake in ADMA Biologics in the fourth quarter valued at $51,000. AlphaQuest LLC acquired a new stake in ADMA Biologics in the fourth quarter valued at $84,000. Finally, CIBC Private Wealth Group LLC raised its position in ADMA Biologics by 137.1% during the 4th quarter. CIBC Private Wealth Group LLC now owns 5,108 shares of the biotechnology company's stock worth $95,000 after purchasing an additional 2,954 shares during the last quarter. Institutional investors own 75.68% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ADMA. Raymond James upped their price target on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research report on Thursday, May 8th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 target price on shares of ADMA Biologics in a report on Tuesday, March 4th. Finally, StockNews.com downgraded shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, ADMA Biologics has a consensus rating of "Moderate Buy" and an average target price of $24.25.

ADMA Biologics Trading Up 2.6%

ADMA Biologics stock traded up $0.49 during trading hours on Friday, reaching $19.69. 2,523,120 shares of the company's stock were exchanged, compared to its average volume of 3,711,941. The firm's 50 day simple moving average is $20.44 and its 200 day simple moving average is $18.82. ADMA Biologics, Inc. has a twelve month low of $8.91 and a twelve month high of $25.67. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $4.68 billion, a PE ratio of 70.32 and a beta of 0.57.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.02). The business had revenue of $114.80 million for the quarter, compared to the consensus estimate of $116.40 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The firm's revenue for the quarter was up 40.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.08 EPS. Research analysts predict that ADMA Biologics, Inc. will post 0.51 earnings per share for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.